---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-015210"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:35:51.286827+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026

## Summary
- Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.
- Revenue $3.4M, including $2.2M French arimoclomol EAP reimbursement and $1.2M AZSTARYS royalties.
- OLPRUVA commercial launch: 4 patient enrollments, ~75% covered lives as of May 1, 2024.
- Arimoclomol NDA PDUFA date set for September 21, 2024; KP1077 positive Phase 2 IH data.
- Debt refinancing with up to $100M; $60M drawn, net $14M added to cash; runway extends into 2026.

## SEC filing metadata
- accession: 0001437749-24-015210
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/0001437749-24-015210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/zvra20240403_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-015210
- JSON: https://secwatch.observer/filing/0001437749-24-015210.json
- Plain text: https://secwatch.observer/filing/0001437749-24-015210.txt

## Key facts
- Earnings Releases
  ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: revenue $3.4 million, net income ($16.6) million, EPS ($0.40) per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $3.4 million
  - Net income: ($16.6) million
  - EPS: ($0.40) per basic and diluted share
  - Result: reported results
  source text: patients currently enrolled and to preserve the value of the program while conducting our portfolio review. Overview of Q1 2024 Financial Results: Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023. The components of revenue during the first quarter included $2.2 million in net reimbursements from the French EAP for
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774924015210/0001437749-24-015210-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.